ResultsWe identified 9,334 records across five compounds: ketamine 5,704 (61.1%), LSD 1,497 (16.0%), DMT 1,047 (11.2%), psilocybin 999 (10.7%), and psilocin 87 (0.9%). Ketamine led in total and annual volume, with the highest single-year counts (480 in 2024; 475 in 2025). Psilocybin showed the fastest growth, increasing from 12 publications in 2015 to 194 in 2025 (CAGR ≈32.1%) and setting consecutive highs in 2023 (n=148), 2024 (n=187), and 2025 (n=194). DMT rose from 30 (2015) to 112 (2025; CAGR ≈14.1%), peaking in 2024 (n=122). LSD increased from 38 (2015) to 117 (2025; CAGR ≈11.9%) with a 2024 peak (n=122). Psilocin remained small but accelerated from 3 (2015) to 18 (2025; CAGR ≈19.6%), peaking in 2025 (n=18). Concentration in 2021–2025 varied by compound: psilocybin 74.0% (739/999), psilocin 63.2% (55/87), DMT 52.3% (548/1,047), ketamine 38.9% (2,221/5,704), and LSD 34.9% (523/1,497). LSD shows sustained activity since the late 1960s; ketamine has grown steadily over five decades; psilocybin and DMT surged in the 2020s. The most studied compound was ketamine (5,704/9,334; 61.1%). Among serotonergic psychedelics, psilocybin achieved the largest contemporary annual total (n=194 in 2025).
Disclosure of InterestM. Pastuszak Grant / Research support from: Beckley Psytech, Compass Pathways, GH Research, MSD, K. Jakuszkowiak-Wojten Grant / Research support from: Alkermes, Allergan, Auspex Pharmaceuticals, Biogen, Cephalon, GH Research, GWPharmaceuticals, Janssen, KCR, Lilly, Lundbeck, Minerva, Orion, Otsuka, and Servier. Maria Gałuszko‐Węgielnik has received research support from: Alkermes, Biogen, Celon, Janssen, GH Research, KCR, Minerva Neurosciences, Lilly, and Servier, Novartis,Compass Pathways, M. Gałuszko-Węgielnik Grant / Research support from: Alkermes, Biogen, Celon, Janssen, GH Research, KCR, Minerva Neurosciences, Lilly, and Servier, Novartis,Compass Pathways, A. Kwaśny Grant / Research support from: Beckley Psytech, Compass Pathways, GH Research, MSD, A. Mechlińska: None Declared, D. Świeczkowski: None Declared, W. Cubała Grant / Research support from: Grants: Acadia, Alkermes, Allergan, Angelini, Auspex Pharmaceuticals, Beckley Psytech, BMS, Celon, Cephalon, Compass Pathways, Cortexyme, Ferrier, Forest Laboratories, GedeonRichter, GH Research, GWPharmaceuticals, HMNC Brain Health, IntraCellular Therapies, Janssen, KCR, Lilly, Lundbeck, MindMed, Minerva, MSD, NIH, Neumora, Novartis, Orion, Otsuka, Recognify Life Sciences, Sanofi, Seaport, Servier Honoraria: Adamed, Angelini, AstraZeneca, BMS, Celon, GH Research, GSK, Janssen, KRKA, Lekam, Lundbeck, Minerva, NeuroCog, Novartis, Orion, Pfizer, Polfa Tarchomin, Sanofi, Servier, Zentiva Advisory boards: Angelini, Celon (ended 2021), Douglas Pharmaceuticals, GH Research, Janssen, MSD, Novartis, Polpharma, Sanofi, Tasman Therapeutics